Please assess the completion status of the following clinical trial:

Trial Title: MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Enrolled in the Parent study, CLS1001-301, through Visit 8/Month 6~* Willing and able to provide written informed consent prior to any study procedures; willing to comply with the instructions and attend all scheduled study visits~Exclusion Criteria:~* Received additional therapy for the treatment of uveitis or prohibited medication~* Require additional therapy for the treatment of uveitis or prohibited medication at the time of the Crossover visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 4 mg CLS-TA Suprachoriodal Injection (Type: None): Those subjects randomized to the CLS-TA 4 mg arm in CLS1001-301 (NCT02595398) and who completed participation without receiving additional therapy. No study drug was administered during this study.
- Sham procedure (Type: None): Those subjects randomized to the sham procedure arm in CLS1001-301 (NCT02595398) and who completed participation without receiving additional therapy. No study drug was administered during this study.

Based on this trial design, predict the completion outcome and termination type (if applicable).